DexCom (DXCM) Tops Q3 EPS by 2c, Maintains Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Atlassian results seen as 'game changer' for AI kills software worries
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
DexCom (DXCM) PT Raised to $86 at Bernstein SocGen Group
October 25, 2024 6:25 AM EDTBernstein SocGen Group analyst Lee Hambright raised the price target on DexCom (NASDAQ: DXCM) to $86.00 (from $82.00) while maintaining a Market Perform rating.
The analyst comments "In-line quarter. Revenue grew 3% organic, landing at the high-end of the reduced guidance range that DXCM set on the Q2 call (1% to 3%). U.S. sales declined -2% organic,... More
BTIG Reiterates Buy Rating on DexCom (DXCM)
October 25, 2024 5:23 AM EDTBTIG analyst Marie Thibault reiterated a Buy rating and $120.00 price target on DexCom (NASDAQ: DXCM).
The analyst comments "Dexcom reported $994.2M in Q3 revenue (+2% y/y rep., +3% y/y org.), $4M above the consensus estimate of $990M. Q3 adj. EPS was $0.45, two cents above consensus. DXCM missed Visible Alpha consensus' U.S. sales expectation by $19M, reporting $701.9M (-2% y/y) and beat by $22M on OUS sales of $292.3M (+12% y/y rep.). Despite the light U.S. result, management commentary was upbeat, highlighting a record level of new patient starts, progress and momentum on... More
